泌乳素瘤是功能性垂体腺瘤中最常见的类型，约占垂体腺瘤的50%。中药联合溴隐亭治疗泌乳素瘤是临床最重要的治疗方法之一。课题组临床长期运用化痰祛瘀之垂宁方可增效溴隐亭的抗肿瘤效应，显著降低毒副作用。研究证实：miR-26b是参与调控垂体腺瘤发生、发展的重要环节，与溴隐亭的耐药形成机制，多巴胺受体（D2R）亚型失衡密切相关。申请者前期采用miRNA芯片发现垂宁方显著下调患者血清miR-26b表达，而该方是否通过miR-26参与调控D2R亚型表达仍不清楚。鉴于此，我们拟分别采用miRNA质粒转染，ddPCR，Luciferase，CFSE荧光标记与裸鼠肿瘤接种等技术，从体内、体外不同角度，验证“垂宁方通过下调miR-26b，影响D2R不同分型及相关靶基因的转录，从而拮抗泌乳素瘤对溴隐亭耐药效应”的科学假说。本项目有可能为中西医结合治疗泌乳素瘤的临床运用提供科学依据，具有潜在的实用价值。

Prolactinoma is the most common type of functional pituitary adenoma, accounting for about 50% of all pituitary adenoma. The Combination of traditional Chinese medicine and bromocriptine on pituitary adenoma is one of the most important methods of clinical treatment. Previous study of our group found that ChuiNing formula (Based on TCM theory of Dissipating Phlegm and Removing Blood Stasis) can assist the synergism of bromocriptine, and significantly reduce toxicity side effect. The latest studies have confirmed that miR-26b is involved in the regulation of pituitary adenomas, a key impact on the formation and development of pituitary adenoma, and also involved in the mechanism of bromocriptine resistance (dopamine receptor subtype expression imbalance). We has found that ChuiNing formula significantly decreased serum miR-26b expression. So the relationship between dopamine receptor is worth for further study. In view of this, we proposed the hypnosis that ChuiNing formula affect D2R different types expression and other relative target gene’s transcription through down regulation of miRNA-26b. In this proposal, miR-26b plasmid transfection, ddPCR, Luciferase, CFSE technologies will have been examined for the combination treatment of Chuining formula and bromocriptine on nude mice xenograft model with human pituitary adenoma cells. The successful validation of the hypothesis will be valuable for integrated traditional Chinese and Western medicine treatment of pituitary adenoma in clinic.